Amgen (AMGN) Azione Prezzo

Amgen Inc is primarily active in the biotechnology industry.

The main competitors of Amgen Inc in the market are Johnson & Johnson, Novartis AG, Pfizer Inc, and Roche Holding AG.

Amgen Inc. is a biotechnology company that was founded in 1980. It has its headquarters in Thousand Oaks, California. The company specializes in developing and manufacturing human therapeutics. Amgen Inc. has a rich history of groundbreaking innovations and advancements in the field of biotechnology. It has introduced numerous successful drugs and therapies, including Epogen, Neupogen, and Enbrel, which have had a significant impact on the treatment of various diseases. Amgen Inc. has grown into one of the largest biotechnology companies globally and continues to strive for advancements in medical science to improve patients' lives.

Amgen Inc has achieved several significant milestones throughout its history. It pioneered the development and commercialization of biotechnology-based medicines, leading to groundbreaking treatments for various diseases. Notably, Amgen's introduction of Epogen revolutionized the treatment of anemia in patients with chronic kidney disease. The company also played a crucial role in advancing the science of targeted therapies with the launch of drugs like Neulasta and Neupogen, enhancing cancer patient care. Additionally, Amgen has expanded its portfolio with innovative drugs addressing osteoporosis, psoriasis, and migraine prevention. Through continuous research and advancements, Amgen Inc remains at the forefront of biopharmaceutical innovation.

Amgen Inc is primarily present in the United States, with its headquarters located in Thousand Oaks, California. The company also has a significant presence in various other countries and regions including Europe, Canada, Japan, and Australia. With a global reach, Amgen Inc operates in many key markets worldwide, leveraging its expertise and innovative portfolio of biopharmaceutical products to improve patients' lives.

Amgen Inc represents values such as integrity, excellence, and a commitment to patients. The corporate philosophy of Amgen focuses on innovative science, delivering life-changing medicines, and addressing unmet medical needs. Amgen aims to improve the health and well-being of individuals worldwide through their cutting-edge research and development efforts. With a strong emphasis on scientific rigor, ethical practices, and patient-centered approach, Amgen is dedicated to pioneering breakthrough therapies to advance medical care and make a positive impact on society.

Gli analisti fissano attualmente un prezzo obiettivo medio di 379,11 USD per l’azione Amgen (mediana: 384,00 USD), pari a -1,4 % rispetto all’ultimo prezzo. Il consenso si basa su 43 giudizi di analisti.

Amgen Prezzi Obiettivo Analisti 2026

43 analisti valutano attualmente l’azione Amgen: 20 raccomandano l’acquisto, 20 la tenuta e 3 la vendita. Per il 2026 gli analisti si aspettano per Amgen ricavi pari a 38,96 miliardi USD e un utile per azione di 23,03 USD.

Amgen Prezzi Obiettivo Analisti 2026

Convertita al tasso di cambio attuale, l’azione Amgen quota 335,49 EUR (385,05 USD).

L’azione Amgen (AMGN) è quotata su 10 borse, tra cui: NASDAQ (AMGN), London (0R0T.L), SIX (Zürich) (AMGN.SW), XETRA (AMG.DE), Frankfurt (AMG.F), München (AMG.MU), Düsseldorf (AMG.DU), Hamburg (AMG.HM).

Amgen Inc. is a biotechnology company that focuses on the development, manufacturing, and marketing of biopharmaceuticals. The company was founded in 1980 and is headquartered in Thousand Oaks, California. Amgen is a key player in the biotechnology field with over 21,000 employees worldwide. Amgen has several divisions, including oncology, hematology, nephrology, bone metabolism, and inflammation. In oncology, Amgen offers various drugs for the treatment of cancer, including Blincyto, Vectibix, and Neulasta. In hematology, the company has developed Aranesp and Epogen for the treatment of anemia. Additionally, Amgen also offers various products for the treatment of kidney diseases such as Sensipar and Parsabiv. In the field of bone metabolism, Amgen provides medications for the treatment of osteoporosis, such as Prolia and Xgeva. In the field of inflammation, Amgen has developed Enbrel for the treatment of rheumatoid arthritis and other inflammatory diseases. Amgen also holds a significant position in the biosimilars market. Biosimilars are imitations of biological drugs that are already on the market. They allow patients to access more affordable treatment options while still providing the same effectiveness and safety as the original product. Amgen has several biosimilars on the market, including Amgevita and Mvasi. Amgen's business model is based on the development of new biopharmaceuticals and biosimilars. The company invests significant financial resources in research and development to create innovative products that aim to improve the health and well-being of patients. Amgen also collaborates closely with other companies and research institutions to find creative solutions for medical challenges. To implement its business model, Amgen has built a global network of production and distribution centers to distribute its products worldwide. The company also has a team of disease-fighting experts, as well as researchers and engineers who work closely together to develop and improve new products. Overall, Amgen has a strong business model based on the development of biopharmaceuticals and biosimilars. The company produces high-quality products to enhance the health of patients worldwide. With a dedicated team of professionals focusing on research, development, and disease-fighting, Amgen is well-positioned to continue creating innovative solutions for medical challenges and expanding its market share.

Il attesa fatturato di Amgen ammonta a 38,96 miliardi USD. Questo dato si basa sui dati finanziari attuali e riflette lo sviluppo commerciale dell'azienda.

Il attesa profitto di Amgen ammonta a 12,51 miliardi USD. L'utile netto riflette la redditività dell'azienda dopo la deduzione di tutti i costi.

Il rapporto prezzo/utili (P/E) di Amgen è attualmente 16,72. Il rapporto P/E confronta il prezzo attuale dell'azione con l'utile per azione e aiuta gli investitori a valutare la valutazione dell'azione Amgen.

Il rapporto prezzo/fatturato (P/S) di Amgen è attualmente 5,37. Il rapporto P/S confronta la capitalizzazione di mercato con il fatturato annuo e funge da indicatore di valutazione dell'azione Amgen.

Il Quality Score AlleAktien per Amgen è 6/10.

L'ISIN di Amgen è US0311621009. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.

Il WKN di Amgen è 867900. Il WKN (Wertpapierkennnummer) è un codice identificativo tedesco a sei cifre per i titoli.

Il ticker di Amgen è AMGN. Con questo simbolo di borsa vengono negoziate le azioni Amgen in borsa.

Negli ultimi 12 mesi, Amgen ha pagato un dividendo di 9,52 USD . Ciò corrisponde a un rendimento da dividendo di circa 2,47 %. Per i prossimi 12 mesi, si prevede che Amgen pagherà un dividendo di 10,89 USD.

Il rendimento da dividendo attuale di Amgen è 2,47 %.

Amgen paga un dividendo, distribuito nei mesi di novembre, febbraio, maggio, agosto.

Amgen ha pagato dividendi ogni anno negli ultimi 15 anni.

Per i prossimi 12 mesi, si prevedono dividendi per un importo di 10,89 USD. Ciò corrisponde a un rendimento da dividendo di 2,90 %.

Amgen è assegnato al settore 'Sanità'.

Per ricevere l'ultimo dividendo di Amgen del 11/09/2026 per un importo di 2,52 USD, dovevi avere il titolo nel tuo portafoglio prima della data di stacco il 21/08/2026.

L'ultimo dividendo è stato distribuito il 11/09/2026.

Nell'anno 2025, Amgen ha distribuito 9,52 USD come dividendi.

I dividendi di Amgen sono distribuiti in USD.